2024

1. Behavioral therapy in migraine: Expanding the therapeutic arsenal

   European Journal of Neurology

2. Clinical and Epidemiological Characteristics of the 2022 Mpox Outbreak in Spain (CEME-22 Study)

   Open Forum Infectious Diseases, Vol. 11, Núm. 3

3. Correction in article by Juzga-Corrales et al. “Characteristics and outcomes of the Spanish registry for pediatric patients with bicuspid aortic valve (REVAB)”, Rev Esp Cardiol. 2023;76:961-969 (Revista Española de Cardiología (English Edition) (2024) 77(4) (358–359), (S1885585724000331), (10.1016/j.rec.2023.12.011))

   Revista Espanola de Cardiologia

4. Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))

   Autoimmunity Reviews

5. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry

   Neuromuscular Disorders, Vol. 34, pp. 1-8

6. Different Mutational Profiles of Subcutaneous Panniculitis-like T-cell Lymphoma and Lupus Panniculitis: An Additional Case Series

   Actas Dermo-Sifiliograficas

7. Effect of CPAP Treatment on Cardiovascular Outcomes

   Archivos de Bronconeumologia, Vol. 60, Núm. 10, pp. 627-633

8. Elevated cholesterol in ATAD3 mutants is a compensatory mechanism that leads to membrane cholesterol aggregation

   Brain, Vol. 147, Núm. 5, pp. 1899-1913

9. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

   Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

10. Exploring the genetics of airflow limitation in lung function across the lifespan – a polygenic risk score study

    eClinicalMedicine, Vol. 75

11. Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 16, Núm. 2

12. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

13. Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction

    Clinical Research in Cardiology, Vol. 113, Núm. 8, pp. 1171-1182

14. Inhibition of BRD4 Attenuates ER Stress-induced Renal Ischemic-Reperfusion Injury

    International Journal of Biological Sciences, Vol. 20, Núm. 5, pp. 1547-1562

15. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

16. Long-term effect of obstructive sleep apnoea management on blood pressure in patients with resistant hypertension: the SARAH study

    The European respiratory journal, Vol. 64, Núm. 2

17. Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results

    Alzheimer's and Dementia, Vol. 20, Núm. 5, pp. 3525-3542

18. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

19. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

    PLOS Digital Health, Vol. 3, Núm. 7

20. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

    The Lancet Haematology, Vol. 11, Núm. 2, pp. e136-e146